New shot shows promise in lowering 'Bad' cholesterol in large trial
NCT ID NCT07295418
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 study tested a new injectable drug called SAL003 in 618 adults with high cholesterol or mixed dyslipidemia. Participants received either SAL003 or a placebo every 4 weeks for 12 weeks, then all received SAL003 for another 40 weeks. The main goal was to see if SAL003 lowers LDL ('bad') cholesterol more than placebo. The trial is complete, but results are not yet available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SAL003 (a PCSK9 inhibitor injection)
What this could lead to
If successful, SAL003 could offer a new injectable option to help lower 'bad' LDL cholesterol in people with high cholesterol, potentially reducing heart disease risk.
What could go wrong
This is a completed Phase 3 trial, but results are not yet published. The drug may not prove superior to placebo or may have side effects. It is tested only in Chinese adults, so results may not apply to other populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERLIPIDEMIAS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University Third Hospital
Beijing, Beijing Municipality, 100083, China